Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
July 11th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and FRONTAGE
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Hong Kong stock market anomaly | CRO concept stocks collectively rose in the afternoon. The Fed's interest rate hiking cycle is nearing its end, and overseas CXO demand is expected to improve first.
Afternoon rally in CRO concept stocks, as of press time, Tigermed (03347) rose 9.85% to HKD 29.55; Frontage (01521) rose 6.58% to HKD 0.81; Pharmaron (03759) rose 4.72% to HKD 8.65; Asymchem Laboratories (06821) rose 2.47% to HKD 47.65; Wuxi Bio (02269) rose 1.97% to HKD 11.4.
Express News | BlackRock's Long Position in WuXi Biologics Increases to 5.23% on June 28 From 4.68% - HKEX Filing
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target Is HK$14
03:31 AM EDT, 06/27/2024 (MT Newswires) -- Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14 Price (HKD): $11.70, Change: $-0.50, Percent Change: -4.10%
Wuxi Bio (02269.HK) received shareholding of 1.445 million shares from Director Li Ge.
According to the latest equity disclosure information from the Stock Exchange, on June 24, 2024, Wuxi Bio(02269.HK) non-executive director and chairman Li Ge acquired 1.445 million shares at an average price of HKD 11.5735 per share, involving approximately HKD 16.7237 million. After the shareholding, Li Ge's latest shareholding is 592,902,633 shares, and the shareholding ratio has increased from 14.24% to 14.28%.
Wuxi Bio (02269.HK) Chairman Li Ge increased shareholding by 1 million shares.
According to the latest equity disclosure of the HKEX, on June 21, 2024, Wuxi Bio(02269.HK) received Li Ge, the non-executive director and chairman, for shareholding of 1 million shares at an average price of HKD 11.6367 per share, with a total amount of approximately HKD 11.637 million. After the shareholding, Li Ge's latest shareholding number increased from 14.22% to 14.24%.
Wuxi Bio (02269) saw a rise of more than 5% in the afternoon stock market, the company previously responded to the reason for the suspension of construction of the Worcester base in the United States.
Wuxi Bio (02269) rose more than 5% in the afternoon. As of the time of publication, it rose 3.28%, with a price of HK$11.98 and a turnover of HK$393 million.
Wuxi Bio (02269.HK) received a shareholding of 200,000 shares from Chairman Li Ge.
On June 20, 2024, according to the latest equity disclosure information of the Hong Kong Stock Exchange, Wuxi Bio (02269.HK), in which Li Ge is a non-executive director and chairman, increased its shareholding by 200,000 shares on the exchange with an average price of HKD 11.9171 per share, involving a total of approximately HKD 2.3834 million. After the shareholding increase, Li Ge's latest holding amount is 590,457,633 shares, and the shareholding ratio has increased from 14.21% to 14.22%.
Market Chatter: Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment
Wuxi Biologics (cayman) (HKG:2269) downplayed its shelved plans for expanding the Massachusetts plant in the US as "normal business adjustment," Yicai Global reported Tuesday. The company did not disc
Wuxi Bio has granted 434,200 restricted shares according to the restricted share incentive plan.
Wuxi Bio (02269) announced that on June 18, 2024, it had approved the granting of a total of 434,200 restricted share units as part of the restricted share unit incentive plan. However, it is subject to the acceptance of the restricted share unit incentive plan by the grantees before it can become effective.
Wuxi Bio (02269.HK) granted a total of 434,000 restricted shares.
On June 18, Gelunhui announced that the board of directors of Wuxi Bio (02269.HK) granted a total of 434,227 restricted stock unit awards on June 18, 2024, but it needs to be accepted by the restricted stock unit award plan grantee according to the restricted stock unit award plan before it can take effect.
Trending Industry Today: TIGERMED Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
June 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending lower today with 9 constituents down and TIGERMED leading Losses.$TIGERMED
Wuxi Biologics Repurchased 1.81M Shares for an Aggregate HK$19.92M
Wuxi Biologics Repurchased 1.81M Shares for an Aggregate HK$19.92M
Wuxi Biologics Shares Up 16% Midday After News of Share Buyback
Wuxi Biologics Shares Up 16% Midday After News of Share Buyback
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
June 12th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending higher today with 8 constituents up and WUXI BIO leading Gains.$WUXI BIO(0
Wuxi Bio (02269) spent HKD 19.9234 million on June 11 to repurchase 1.81 million shares.
Wuxi Bio (02269) announced that on June 11, 2024, the company spent HKD 19.9234 million ...